

# CEO BOARD UPDATE

Seth Berkley, CEO




Board meeting  
30 November–2 December 2021

[www.gavi.org](http://www.gavi.org)

# Gavi 5.0 year 1, pandemic year 2: risks, uncertainties persist

## Bimonthly change in confirmed COVID-19 cases (29 November 2021)



Evidence of detrimental change in COVID-19 epidemiology  
B.1.1.529 designated as VOC

**Need for variant-adapted vaccines  
in case of variant-escaping immunity**

The bimonthly growth rate on any given date measures the percentage change in number of new confirmed cases over the last 14 days relative to the number in the previous 14 days.

Source: John Hopkins University CSSE COVID-19 Data – Last updated 30 November, 08:05 (London time) OurWorldInData.org/coronavirus • CC BY

# Lower-income countries face increased economic pressure despite global growth signals



*Gavi, the Vaccine Alliance also provided financial support for this work*

## World Bank


“The COVID-19 pandemic has resulted in a double shock – health and economic ... and triggered an economic recession surpassing any economic downturn since World War II.”

## Gavi-supported countries face acute challenges:

- contracting fiscal space
- rising debt
- financing COVID-19 response
- continued risks to government health spending

~**US\$ 400bn debt increase** in 2020 for 57 Gavi 5.0-supported countries over 2019

# 2021–2025 Vaccine Alliance priorities: equity agenda across RI, ZDC, COVID-19



Maintain, restore  
and strengthen  
routine immunisation



Reach zero-dose children,  
missed communities



2022: Ensure equal access  
to COVID-19 vaccines

- Maintain supply predictability
- Support enhanced delivery, prioritising Gavi COVAX AMC countries

“  
*The largest increase in unvaccinated children in 20 years and critical gaps in disease surveillance increase risk of measles outbreaks, putting lives at risk: WHO, CDC*

Global progress against measles threatened amidst COVID-19 pandemic  
(10 November 2021 news release)

# DRC: competing priorities need agility in Gavi support



Nov. 2021. Credit: Gavi/MNKF Creatives

- Public health spending lower than in other countries; renewed commitment from President Tshisekedi for domestic funding for vaccines in October 2021; Gavi, Gates Foundation, World Bank, IMF jointly engaged with national authorities towards increasing government health expenditure
- Finding zero-dose children through mapping, targeting through Mashako Plan; innovative tools; plan to access Equity Accelerator Funding in Q2 2022
- High risk of delays to routine immunisation catch-up, introduction of new vaccines (MCV2, IPV2) due to COVID-19 vaccine scale-up, multi-campaign rounds
- High vaccine hesitancy, miscommunication & misinformation: slow uptake of COVID-19 vaccines

# Ethiopia: political crisis threatens programmatic efforts


---




- Political, security challenges since Nov. 2020; repercussions will be felt far into the future
- Pressure on **domestic financing**; MoH assures donor health funds **will not be diverted** to war efforts; audit scheduled for Q1 2022
- Gavi investments and **zero-dose agenda delayed**; Alliance partners working with MoH on planning; contracting surge support to enhance programme management capacity
- Mobile health & nutritional teams providing essential services (inc. immunisation) to refugees, IDPs in conflict areas, IDP sites; ~17% of districts inaccessible due to conflict
- Gavi approved ~US\$ 15M early CDS funds to support COVID-19 vaccination scale-up, but progress slow

# Global wild poliovirus type 1 positive isolates: Afghanistan and Pakistan


2019<sup>1</sup>



2020



2021




<sup>1</sup>Onset of paralysis/collection date: 01 Jan. to 31 Dec. 2019


- WPV1 acute flaccid paralysis (AFP): 176
- ◻ WPV1 environmental surveillance (ES): 439
- ◻ Endemic country (WPV1)

	WPV1 cases	
	Pakistan	Afghanistan
2019	147	29
2020	84	56
2021	1	3

# Pakistan: wild poliovirus type 1 cases, environmental surveillance, 2020–2021




No WPV1 case



One WPV1 ES+




# Pakistan: critical juncture, key opportunities



- Highest level of Gavi support: US\$ 1.7 billion
- Lowest number of polio cases in Pakistan's history; potentially on verge of [halting polio transmission](#)
- [Polio Oversight Board](#) in Pakistan (22–26 Nov.): advocacy for strong final push in remaining corridors & integration with EPI – innovative, integrated, bottom-up approaches required, including coordination with Afghanistan
- National [MR/OPV campaign](#): [92.7M children](#) up to 15 years in 12 days achieved ~100% administrative coverage; strategies in place for mop-up campaigns
- [COVID-19 vaccine programme](#) a global example: central leadership, effective systems built on EPI, PEI; innovative use of digital tools
- Preparing to [operationalise UHC/PHC reforms](#): to ensure EPI (including polio vaccines, COVID-19 infrastructure), reaching zero-dose children are core components of integrated service delivery

# Inequities in COVID-19 vaccination

Cumulative COVID-19 doses administered by country income group in 2021, % of global total (as of 29 November 2021)



Only 30% of COVID-19 vaccine doses administered in lower-income countries – yet they account for 51% of the world's population

Sources: Our World in Data (December 2020–February 2021); WHO COVID-19 Dashboard (March 2021 onwards); World Bank (income groups)

# COVAX: ramping up COVID-19 vaccine shipments

## unicef | COVAX Implementation Overview

Map Details Allocation

The Implementation Overview dashboard presents allocated COVID-19 vaccine doses, contracted with suppliers, on shipment and delivered to countries and territories.

Doses Allocated	Doses Ordered, cumulative	Doses released for shipment, cumulative	Doses on shipment in transit	Doses Shipped, cumulative	Countries and territories, doses shipped
1,395,161,377	764,248,950	677,439,942	5,292,750	586,164,536	144

Region: All

Participant: All


Vendor Name: All

AMC/SFP: All

Allocation reference: All

Planned shipments

Participant	Planned Shipment Arrival
Bangladesh	01/12/2021
Fiji	01/12/2021
Kenya	01/12/2021
Nepal	01/12/2021
Pakistan	01/12/2021





**29–30 Nov. 2021:  
11M doses shipped –  
strongest daily  
shipment to date**

Source: <https://cpp.unicef.org/dashboard/1>. Accessed on 1 December 2021, 1051hr

# COVID-19 vaccine supply: from “available” to “shots in arms” requires prep, time

**COVAX available supply under most likely scenario**  
cumulative, million doses, 2021

■ Gavi COVAX AMC volume  
■ Maximum SFP volume



\*\*Doses net (no doubling of J&J doses)

\* ~20% coverage in AMC91 countries is 1.13bn doses (net), including 10% wastage and excluding doses to India

Source: COVAX Global Supply Forecast

# Countries step up to donate doses; recipients call for longer shelf lives, predictability, un-earmarked doses

## Confirmed additional supply

	Donations announced Gavi COVAX AMC+SFP+bilateral 2021–2022	of which formal offers <sup>1</sup> Gavi COVAX AMC+SFP	of which shipped by Gavi COVAX AMC / (AMC+SFP)	Q1 2022	Q2 2022
Australia	60	0.0	0 / (0)	0	0
Canada	51 <sup>7</sup>	15.1	6.7 / (8.4)	0	0
Team Europe	464 <sup>2,6</sup>	308	51 / (59)	85 <sup>9</sup>	10 <sup>9</sup>
Belgium	8.6	8.2	2.5 / (2.7)	0	0
Czech Republic	1.9	1.3	0 / (0)	0	0
Denmark	6.0	4.7	0.8 / (1)	0	0
Finland	3.7	1.4	0.1 / (0.1)	0	0
France	120 <sup>2</sup>	64.1	19.0 / (19.0)	0	0
Germany	175 <sup>2</sup>	99.1	14.1 / (14.9)	0	0
Greece	3 <sup>2</sup>	2.6	0.5 / (0.5)	0	0
Ireland	1.3	1.3	0 / (0)	0	0
Italy	45 <sup>2</sup>	43.9	6.1 / (8.2)	0	0
Netherlands	27	16.3	0 / (0)	0	0
Norway	6	5.9	1.5 / (1.5)	0	0
Portugal	3.2 <sup>2</sup>	2.4	0.3 / (0.3)	0	0
Slovakia	1.3	1.0	0 / (0)	0	0
Slovenia	1.2	1.1	0 / (0)	0	0
Spain	50 <sup>2</sup>	46.3	3.3 / (8.1)	0	0
Sweden	6.2	5.9	3.0 / (3.0)	0	0
Others <sup>3</sup>	4.4	3 <sup>5</sup>	0.1 / (0.1)	0	0
Hong Kong SAR China	7.5	7.5 <sup>8</sup>	0 / (0)	4	0
Japan	60 <sup>2</sup>	11.3	8.4 / (11.3)	0	0
Macao SAR China	0.4	0.0	0 / (0)	0	0
New Zealand	3.8	0.9	0.9 / (0.9)	0	0
South Korea	4.8	0.0	0 / (0)	0	0
Switzerland	4	1.6	0.5 / (0.5)	0	0
Turkey	10	0.0	0 / (0)	0	0
UAE	1	0.0	0 / (0)	0	0
UK	100	26.2	8.0 / (8.0)	0	0
USA	857.5 <sup>4</sup>	193.4	130.7 / (140.3)	200	300
<b>Total</b>	<b>1,624</b>	<b>564</b>	<b>206 / (229)</b>	<b>289</b>	<b>310</b>

As of 29 November 2021


Forecast supply to Gavi COVAX AMC by end Q2 2022 estimated at ~1,092M (formal offers + confirmed additional supply).<sup>10</sup>

Note: volumes offered to COVAX are subject to change based on supply information from manufacturers. If supply does not meet COVAX requirements (e.g. shelf life <10 weeks in country), these numbers could be lower.

100m–200m additional doses to be shipped by end of year

# COVAX: low-income countries' primary source of COVID-19 vaccines; important source for lower middle-income countries

Delivered doses to date by market channel, %




Note: 41% of doses delivered as unknown

Source: UNICEF, COVID-19 Vaccine Market Shaping Strategy, Advisory Group materials, as of November 2021

# Country absorption, coverage aspirations varied

Four-week average daily vaccination rate across Gavi COVAX AMC participants against median four-week average rate across high-income participants as comparator




Source: COVAX Country Readiness and Delivery (CRD) vaccination rate dataset as of 24 November 2021

Note: Two Gavi COVAX AMC participants are not vaccinating: Eritrea, DPR Korea

Absorption remains **heterogenous**:

- **14 countries** with absorption rates **>0.5%** per day; **37 countries** with **>20%** population **fully vaccinated**
- **~20 countries** with absorption rates **<0.15%**

Since June, average **absorption** **increased >3x** from 0.08% to 0.30%



# COVAX, Alliance engagement with AU, AVATT, Africa CDC on COVID-19 response

---



- Regular engagement with African Vaccine Acquisition Task Team (AVATT) leadership, technical teams
- Strong commitment to work together: increase vaccine supply to Africa, ensure countries can absorb doses



# Enhanced AU collaboration: aligning support; learning from Morocco's roll-out

- AU-hosted meeting (Nov. 2021) for first 13 countries supported by Saving Lives and Livelihoods programme
- Gavi Secretariat invited to align engagement, support
- Morocco's successful COVID-19 vaccine roll-out
  - >65% of population fully immunised (four vaccines); now rolling out for aged >12
  - Strong political leadership; robust data-driven management & demand generation; cross-sectoral collaboration
  - Rapidly scaled up mass vaccination sites, with capacity to vaccinate up to 3,000 people per day
- Gavi, AU to identify priority countries for enhanced in-country collaboration



# COVAX: some key concerns in delivery, vaccination

---

## Country readiness and delivery

- Ensuring supply predictability
- Adequate vaccine shelf life
- Management of multiple vaccine products
- Heterogeneity in country absorption rates
- Over-stretched EPI, management
- Adequate availability of ancillary supplies, including syringes
- Adequate cold chain, service delivery
- Vaccine hesitancy, misinformation
- Matching product supply to country preferences

## Global coordination

- Ensuring coordinated action with multilaterals and other agencies – driven by country needs
- Leveraging comparative advantage of Alliance partners for collective, strategic actions
- Innovative solutions
- South to South learnings
- Political challenges in countries

## Resource mobilisation

- Up-front, flexible funding to secure supply, manage risk
- Balance between APAs, cost sharing and dose donations, with a view to sustainability and effectiveness
- Financing for donation ancillaries
- Financing for risk and the unknown in a rapidly changing situation

# Looking ahead: future pandemic preparedness

---

**Goal: robust early warning system with equitable access to counter-measures; lower- and lower middle-income countries critical stakeholders**

- ✔ Strengthen long-term investments in sustainable, universally available routine immunisation as part of a resilient PHC system through Gavi:
  - preventing 18 vaccine-preventable infectious diseases; preventing, mitigating outbreaks in 9 infectious diseases of epidemic potential
  - Strengthening diagnostic capacity towards improved surveillance, targeted vaccination efforts
  - Building resilience through stronger PHC systems
  - Prioritising zero-dose children and missed communities to leave no one behind
- ✔ Leverage momentum from COVID-19 vaccine roll-out
  - Cross-cutting geopolitical support
  - Proven innovative financing instruments (IFFIm, AMC)
  - Foundation for adult immunisation platform
  - Lessons from COVAX: innovations, new partnerships and ways of working
  - Keep systems and innovations warm for use in next pandemic

# THANK YOU

---

